Overview

Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
0
Participant gender:
Female
Summary
This study aims to determine the effect of metformin along with standard cancer treatment, and its effect on the prognosis of the metastatic breast in non-diabetic patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hager salah el din
Treatments:
Metformin
Criteria
Inclusion Criteria:

- The non-diabetic patients will be included in the study if they meet the following
criteria:

1. Confirmed metastatic breast cancer (IV stage) radiologically or by clinical
evaluation receiving chemotherapy

2. Age between 18- 70 years.

3. Life expectancy at least 6 months

Exclusion Criteria:

- The patients will be excluded from the study if they have the following criteria:

1. Bad prognosis disease: Criteria defined as the following

- If patient >70 years

- If patient has bad site metastasis (brain)

2. Hypersensitivity for metformin: if happened patient will be treated as following

• Pheniramine Maleate 3 times daily for 7 days and Tablet Dexamethasone 1mg daily
in 2 divided doses for 5 days [16].

3. Any condition associated with increased risk of metformin-associated lactic
acidosis (e.g., congestive heart failure defined as New York Heart Association
{NYHA} Class III or IV functional status; the history of acidosis of any type,
severe infections, kidney or liver disease, respiratory disease, seizures .

4. Diabetic patients.